Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 80 entries
Sorted by: Best Match Show Resources per page
Closing the information gap between clinical and postmarketing trials: the case of dabigatran.

European heart journal. Cardiovascular pharmacotherapy

Rolden HJ, Grutters JP, van der Wilt GJ, Maas AH.
PMID: 27533988
Eur Heart J Cardiovasc Pharmacother. 2015 Jul;1(3):153-6. doi: 10.1093/ehjcvp/pvv020. Epub 2015 Apr 17.

No abstract available.

Cite
Rolden HJ, Grutters JP, van der Wilt GJ, et al. Closing the information gap between clinical and postmarketing trials: the case of dabigatran. Eur Heart J Cardiovasc Pharmacother. 2015;1(3):153-6doi: 10.1093/ehjcvp/pvv020.
Rolden, H. J., Grutters, J. P., van der Wilt, G. J., & Maas, A. H. (2015). Closing the information gap between clinical and postmarketing trials: the case of dabigatran. European heart journal. Cardiovascular pharmacotherapy, 1(3), 153-6. https://doi.org/10.1093/ehjcvp/pvv020
Rolden, Herbert J A, et al. "Closing the information gap between clinical and postmarketing trials: the case of dabigatran." European heart journal. Cardiovascular pharmacotherapy vol. 1,3 (2015): 153-6. doi: https://doi.org/10.1093/ehjcvp/pvv020
Rolden HJ, Grutters JP, van der Wilt GJ, Maas AH. Closing the information gap between clinical and postmarketing trials: the case of dabigatran. Eur Heart J Cardiovasc Pharmacother. 2015 Jul;1(3):153-6. doi: 10.1093/ehjcvp/pvv020. Epub 2015 Apr 17. PMID: 27533988.
Copy Download .nbib Format: NLM
The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy".

PharmacoEconomics

Grutters JP, van Asselt MB, Chalkidou K, Joore MA.
PMID: 26314283
Pharmacoeconomics. 2015 Sep;33(9):983. doi: 10.1007/s40273-015-0321-8.

No abstract available.

Cite
Grutters JP, van Asselt MB, Chalkidou K, et al. The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". Pharmacoeconomics. 2015;33(9):983doi: 10.1007/s40273-015-0321-8.
Grutters, J. P., van Asselt, M. B., Chalkidou, K., & Joore, M. A. (2015). The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". PharmacoEconomics, 33(9), 983. https://doi.org/10.1007/s40273-015-0321-8
Grutters, Janneke P C, et al. "The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy"." PharmacoEconomics vol. 33,9 (2015): 983. doi: https://doi.org/10.1007/s40273-015-0321-8
Grutters JP, van Asselt MB, Chalkidou K, Joore MA. The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". Pharmacoeconomics. 2015 Sep;33(9):983. doi: 10.1007/s40273-015-0321-8. PMID: 26314283.
Copy Download .nbib Format: NLM
Mechanisms of Invasion Resistance of Aquatic Plant Communities.

Frontiers in plant science

Petruzzella A, Manschot J, van Leeuwen CHA, Grutters BMC, Bakker ES.
PMID: 29479363
Front Plant Sci. 2018 Feb 09;9:134. doi: 10.3389/fpls.2018.00134. eCollection 2018.

Invasive plant species are among the major threats to freshwater biodiversity. Few experimental studies have investigated whether native plant diversity can provide biotic resistance to invaders in freshwater ecosystems. At small spatial scales, invasion resistance may increase with plant...

Cite
Petruzzella A, Manschot J, van Leeuwen CHA, et al. Mechanisms of Invasion Resistance of Aquatic Plant Communities. Front Plant Sci. 2018;9:134doi: 10.3389/fpls.2018.00134.
Petruzzella, A., Manschot, J., van Leeuwen, C. H. A., Grutters, B. M. C., & Bakker, E. S. (2018). Mechanisms of Invasion Resistance of Aquatic Plant Communities. Frontiers in plant science, 9134. https://doi.org/10.3389/fpls.2018.00134
Petruzzella, Antonella, et al. "Mechanisms of Invasion Resistance of Aquatic Plant Communities." Frontiers in plant science vol. 9 (2018): 134. doi: https://doi.org/10.3389/fpls.2018.00134
Petruzzella A, Manschot J, van Leeuwen CHA, Grutters BMC, Bakker ES. Mechanisms of Invasion Resistance of Aquatic Plant Communities. Front Plant Sci. 2018 Feb 09;9:134. doi: 10.3389/fpls.2018.00134. eCollection 2018. PMID: 29479363; PMCID: PMC5811644.
Copy Download .nbib Format: NLM
Phenotypic characterization of human intermediate monocytes.

Frontiers in immunology

Hijdra D, Vorselaars AD, Grutters JC, Claessen AM, Rijkers GT.
PMID: 24155746
Front Immunol. 2013 Oct 22;4:339. doi: 10.3389/fimmu.2013.00339. eCollection 2013.

No abstract available.

Cite
Hijdra D, Vorselaars AD, Grutters JC, et al. Phenotypic characterization of human intermediate monocytes. Front Immunol. 2013;4:339doi: 10.3389/fimmu.2013.00339.
Hijdra, D., Vorselaars, A. D., Grutters, J. C., Claessen, A. M., & Rijkers, G. T. (2013). Phenotypic characterization of human intermediate monocytes. Frontiers in immunology, 4339. https://doi.org/10.3389/fimmu.2013.00339
Hijdra, Daniëlle, et al. "Phenotypic characterization of human intermediate monocytes." Frontiers in immunology vol. 4 (2013): 339. doi: https://doi.org/10.3389/fimmu.2013.00339
Hijdra D, Vorselaars AD, Grutters JC, Claessen AM, Rijkers GT. Phenotypic characterization of human intermediate monocytes. Front Immunol. 2013 Oct 22;4:339. doi: 10.3389/fimmu.2013.00339. eCollection 2013. PMID: 24155746; PMCID: PMC3805031.
Copy Download .nbib Format: NLM
Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A.

Journal of clinical medicine

Wiertz IA, Moll SA, Seeliger B, Barlo NP, van der Vis JJ, Korthagen NM, Rijkers GT, Ruven HJT, Grutters JC, Prasse A, van Moorsel CHM.
PMID: 32575869
J Clin Med. 2020 Jun 21;9(6). doi: 10.3390/jcm9061940.

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic disease, characterized by fibroblast proliferation and extracellular matrix deposition. CC-chemokine ligand 18 (CCL18) upregulates the production of collagen by lung fibroblasts and is associated with mortality. This study was designed to...

Cite
Wiertz IA, Moll SA, Seeliger B, et al. Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. J Clin Med. 2020;9(6)doi: 10.3390/jcm9061940.
Wiertz, I. A., Moll, S. A., Seeliger, B., Barlo, N. P., van der Vis, J. J., Korthagen, N. M., Rijkers, G. T., Ruven, H. J. T., Grutters, J. C., Prasse, A., & van Moorsel, C. H. M. (2020). Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. Journal of clinical medicine, 9(6), . https://doi.org/10.3390/jcm9061940
Wiertz, Ivo A, et al. "Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A." Journal of clinical medicine vol. 9,6 (2020). doi: https://doi.org/10.3390/jcm9061940
Wiertz IA, Moll SA, Seeliger B, Barlo NP, van der Vis JJ, Korthagen NM, Rijkers GT, Ruven HJT, Grutters JC, Prasse A, van Moorsel CHM. Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. J Clin Med. 2020 Jun 21;9(6). doi: 10.3390/jcm9061940. PMID: 32575869; PMCID: PMC7356165.
Copy Download .nbib Format: NLM
Wearable Health Trackers: A Revolution in Cancer Care.

Journal of the National Cancer Institute

Gritters J.
PMID: 30053094
J Natl Cancer Inst. 2017 Mar 01;109(3). doi: 10.1093/jnci/djx046.

No abstract available.

Cite
Gritters J. Wearable Health Trackers: A Revolution in Cancer Care. J Natl Cancer Inst. 2017;109(3)doi: 10.1093/jnci/djx046.
Gritters, J. (2017). Wearable Health Trackers: A Revolution in Cancer Care. Journal of the National Cancer Institute, 109(3), . https://doi.org/10.1093/jnci/djx046
Gritters, Jenni. "Wearable Health Trackers: A Revolution in Cancer Care." Journal of the National Cancer Institute vol. 109,3 (2017). doi: https://doi.org/10.1093/jnci/djx046
Gritters J. Wearable Health Trackers: A Revolution in Cancer Care. J Natl Cancer Inst. 2017 Mar 01;109(3). doi: 10.1093/jnci/djx046. PMID: 30053094.
Copy Download .nbib Format: NLM
Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases").

Orphanet journal of rare diseases

Grimm SE, Pouwels X, Ramaekers BLT, Wijnen B, Knies S, Grutters J, Joore MA.
PMID: 34281581
Orphanet J Rare Dis. 2021 Jul 19;16(1):320. doi: 10.1186/s13023-021-01938-7.

No abstract available.

Cite
Grimm SE, Pouwels X, Ramaekers BLT, et al. Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases"). Orphanet J Rare Dis. 2021;16(1):320doi: 10.1186/s13023-021-01938-7.
Grimm, S. E., Pouwels, X., Ramaekers, B. L. T., Wijnen, B., Knies, S., Grutters, J., & Joore, M. A. (2021). Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases"). Orphanet journal of rare diseases, 16(1), 320. https://doi.org/10.1186/s13023-021-01938-7
Grimm, Sabine E, et al. "Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases")." Orphanet journal of rare diseases vol. 16,1 (2021): 320. doi: https://doi.org/10.1186/s13023-021-01938-7
Grimm SE, Pouwels X, Ramaekers BLT, Wijnen B, Knies S, Grutters J, Joore MA. Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases"). Orphanet J Rare Dis. 2021 Jul 19;16(1):320. doi: 10.1186/s13023-021-01938-7. PMID: 34281581; PMCID: PMC8287680.
Copy Download .nbib Format: NLM
Congenital tracheobronchomegaly (Mounier-Kuhn syndrome) in a 28-year-old Zambian male: a case report.

The Pan African medical journal

Shahin S, Hoffman T, van Es W, Grutters J, Mateyo K.
PMID: 34970395
Pan Afr Med J. 2021 Nov 12;40:153. doi: 10.11604/pamj.2021.40.153.31703. eCollection 2021.

Congenital tracheobronchomegaly, also known as Mounier Kuhn Syndrome (MKS) is a rare respiratory disorder characterized by dilatation of the trachea and bronchi. We report a case of a 28-year-old male of African descent in Zambia, who presented with a...

Cite
Shahin S, Hoffman T, van Es W, et al. Congenital tracheobronchomegaly (Mounier-Kuhn syndrome) in a 28-year-old Zambian male: a case report. Pan Afr Med J. 2021;40:153doi: 10.11604/pamj.2021.40.153.31703.
Shahin, S., Hoffman, T., van Es, W., Grutters, J., & Mateyo, K. (2021). Congenital tracheobronchomegaly (Mounier-Kuhn syndrome) in a 28-year-old Zambian male: a case report. The Pan African medical journal, 40153. https://doi.org/10.11604/pamj.2021.40.153.31703
Shahin, Saifurrahman, et al. "Congenital tracheobronchomegaly (Mounier-Kuhn syndrome) in a 28-year-old Zambian male: a case report." The Pan African medical journal vol. 40 (2021): 153. doi: https://doi.org/10.11604/pamj.2021.40.153.31703
Shahin S, Hoffman T, van Es W, Grutters J, Mateyo K. Congenital tracheobronchomegaly (Mounier-Kuhn syndrome) in a 28-year-old Zambian male: a case report. Pan Afr Med J. 2021 Nov 12;40:153. doi: 10.11604/pamj.2021.40.153.31703. eCollection 2021. PMID: 34970395; PMCID: PMC8683458.
Copy Download .nbib Format: NLM
COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition.

Chest

Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Ribeiro Carvalho CR, Harari S, Koslow M, Grutters JC, Inoue Y, Gupta N, Johnson SR.
PMID: 34942174
Chest. 2021 Dec 20; doi: 10.1016/j.chest.2021.12.640. Epub 2021 Dec 20.

No abstract available.

Cite
Baldi BG, Radzikowska E, Cottin V, et al. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest. 2021;doi: 10.1016/j.chest.2021.12.640.
Baldi, B. G., Radzikowska, E., Cottin, V., Dilling, D. F., Ataya, A., Ribeiro Carvalho, C. R., Harari, S., Koslow, M., Grutters, J. C., Inoue, Y., Gupta, N., & Johnson, S. R. (2021). COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest, . https://doi.org/10.1016/j.chest.2021.12.640
Baldi, Bruno Guedes, et al. "COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition." Chest vol. (2021). doi: https://doi.org/10.1016/j.chest.2021.12.640
Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Ribeiro Carvalho CR, Harari S, Koslow M, Grutters JC, Inoue Y, Gupta N, Johnson SR. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest. 2021 Dec 20; doi: 10.1016/j.chest.2021.12.640. Epub 2021 Dec 20. PMID: 34942174.
Copy Download .nbib Format: NLM
COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition.

Chest

Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Ribeiro Carvalho CR, Harari S, Koslow M, Grutters JC, Inoue Y, Gupta N, Johnson SR.
PMID: 34942174
Chest. 2021 Dec 20; doi: 10.1016/j.chest.2021.12.640. Epub 2021 Dec 20.

No abstract available.

Cite
Baldi BG, Radzikowska E, Cottin V, et al. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest. 2021;doi: 10.1016/j.chest.2021.12.640.
Baldi, B. G., Radzikowska, E., Cottin, V., Dilling, D. F., Ataya, A., Ribeiro Carvalho, C. R., Harari, S., Koslow, M., Grutters, J. C., Inoue, Y., Gupta, N., & Johnson, S. R. (2021). COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest, . https://doi.org/10.1016/j.chest.2021.12.640
Baldi, Bruno Guedes, et al. "COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition." Chest vol. (2021). doi: https://doi.org/10.1016/j.chest.2021.12.640
Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Ribeiro Carvalho CR, Harari S, Koslow M, Grutters JC, Inoue Y, Gupta N, Johnson SR. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest. 2021 Dec 20; doi: 10.1016/j.chest.2021.12.640. Epub 2021 Dec 20. PMID: 34942174; PMCID: PMC8687712.
Copy Download .nbib Format: NLM
Activation of Downstream mTORC1 Target Ribosomal Protein S6 Kinase (S6K) Can Be Found in a Subgroup of Dutch Patients with Granulomatous Pulmonary Disease.

Cells

Kraaijvanger R, Seldenrijk K, Beijer E, Damen J, Wilson JL, Weichhart T, Grutters JC, Veltkamp M.
PMID: 34944053
Cells. 2021 Dec 15;10(12). doi: 10.3390/cells10123545.

Mechanistic target of rapamycin complex 1 (mTORC1) has been linked to different diseases. The mTORC1 signaling pathway is suggested to play a role in the granuloma formation of sarcoidosis. Recent studies demonstrated conflicting data on mTORC1 activation in patients...

Cite
Kraaijvanger R, Seldenrijk K, Beijer E, et al. Activation of Downstream mTORC1 Target Ribosomal Protein S6 Kinase (S6K) Can Be Found in a Subgroup of Dutch Patients with Granulomatous Pulmonary Disease. Cells. 2021;10(12)doi: 10.3390/cells10123545.
Kraaijvanger, R., Seldenrijk, K., Beijer, E., Damen, J., Wilson, J. L., Weichhart, T., Grutters, J. C., & Veltkamp, M. (2021). Activation of Downstream mTORC1 Target Ribosomal Protein S6 Kinase (S6K) Can Be Found in a Subgroup of Dutch Patients with Granulomatous Pulmonary Disease. Cells, 10(12), . https://doi.org/10.3390/cells10123545
Kraaijvanger, Raisa, et al. "Activation of Downstream mTORC1 Target Ribosomal Protein S6 Kinase (S6K) Can Be Found in a Subgroup of Dutch Patients with Granulomatous Pulmonary Disease." Cells vol. 10,12 (2021). doi: https://doi.org/10.3390/cells10123545
Kraaijvanger R, Seldenrijk K, Beijer E, Damen J, Wilson JL, Weichhart T, Grutters JC, Veltkamp M. Activation of Downstream mTORC1 Target Ribosomal Protein S6 Kinase (S6K) Can Be Found in a Subgroup of Dutch Patients with Granulomatous Pulmonary Disease. Cells. 2021 Dec 15;10(12). doi: 10.3390/cells10123545. PMID: 34944053.
Copy Download .nbib Format: NLM
Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes.

ERJ open research

Kampstra NA, van der Nat PB, Dijksman LM, van Beek FT, Culver DA, Baughman RP, Renzoni EA, Wuyts W, Kouranos V, Zanen P, Wijsenbeek MS, Eijkemans MJC, Biesma DH, van der Wees PJ, Grutters JC.
PMID: 31687368
ERJ Open Res. 2019 Oct 30;5(4). doi: 10.1183/23120541.00094-2019. eCollection 2019 Oct.

Our study presents findings on a previously developed standard set of clinical outcome data for pulmonary sarcoidosis patients. We aimed to assess whether changes in outcome varied between the different centres and to evaluate the feasibility of collecting the...

Cite
Kampstra NA, van der Nat PB, Dijksman LM, et al. Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. ERJ Open Res. 2019;5(4)doi: 10.1183/23120541.00094-2019.
Kampstra, N. A., van der Nat, P. B., Dijksman, L. M., van Beek, F. T., Culver, D. A., Baughman, R. P., Renzoni, E. A., Wuyts, W., Kouranos, V., Zanen, P., Wijsenbeek, M. S., Eijkemans, M. J. C., Biesma, D. H., van der Wees, P. J., & Grutters, J. C. (2019). Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. ERJ open research, 5(4), . https://doi.org/10.1183/23120541.00094-2019
Kampstra, Nynke A, et al. "Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes." ERJ open research vol. 5,4 (2019). doi: https://doi.org/10.1183/23120541.00094-2019
Kampstra NA, van der Nat PB, Dijksman LM, van Beek FT, Culver DA, Baughman RP, Renzoni EA, Wuyts W, Kouranos V, Zanen P, Wijsenbeek MS, Eijkemans MJC, Biesma DH, van der Wees PJ, Grutters JC. Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. ERJ Open Res. 2019 Oct 30;5(4). doi: 10.1183/23120541.00094-2019. eCollection 2019 Oct. PMID: 31687368; PMCID: PMC6819983.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 80 entries